Hyma Tanikella Vempaty, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Vempaty’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A61497 · Current
Licensed to practise in California · since 1997 · expires 2028-08-31 · Andhra University, Rangaraya Medical College Aka University of Health Sciences Vijayawada.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Drugs they prescribed that Part D paid
$1,461,058
Pharmacies billed $1,461,058 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (11 of 322) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
222 generic and 100 brand-name prescriptions · $1,461,058 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenalidomide | 28 | $270,450 | $9,659 |
| Pomalyst | 11 | $260,935 | $23,721 |
| Jakafi | 23 | $197,634 | $8,593 |
| Brukinsa | 14 | $89,223 | $6,373 |
| Alvaiz | 13 | $82,230 | $6,325 |
See all 9 drugs
| Lenalidomide | 28 | $270,450 | $9,659 |
| Pomalyst | 11 | $260,935 | $23,721 |
| Jakafi | 23 | $197,634 | $8,593 |
| Brukinsa | 14 | $89,223 | $6,373 |
| Alvaiz | 13 | $82,230 | $6,325 |
| Hydroxyurea | 36 | $1,686 | $47 |
| Acyclovir | 27 | $720 | $27 |
| Dexamethasone | 19 | $466 | $25 |
| Prednisone | 22 | $229 | $10 |
Year by year
| 2024 | 322 | 78 | 3% (11) | 31% | $1,461,058 |
| 2023 | 391 | 73 | 4% (16) | 27% | $1,755,185 |
| 2022 | 385 | 74 | 6% (21) | None | $1,793,359 |
| 2021 | 422 | 70 | 7% (28) | 47% | $2,108,606 |
| 2020 | 446 | 70 | 4% (18) | 46% | $2,126,935 |
| 2019 | 454 | 72 | 6% (28) | 40% | $2,033,381 |
| 2018 | 478 | 70 | 4% (21) | 38% | $2,018,920 |
| 2017 | 473 | 77 | 4% (17) | 38% | $1,654,115 |
| 2016 | 434 | 72 | 6% (24) | 41% | $1,673,996 |
| 2015 | 483 | 79 | 7% (35) | 34% | $1,383,007 |
| 2014 | 503 | 95 | 12% (59) | 31% | $1,058,804 |
| 2013 | 518 | 97 | 17% (88) | None | $696,876 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Lenalidomide | 40 | $457,485 | $11,437 |
| Promacta | 19 | $268,875 | $14,151 |
| Calquence | 12 | $167,813 | $13,984 |
| Jakafi | 12 | $109,877 | $9,156 |
| Atovaquone | 14 | $4,247 | $303 |
| Hydroxyurea | 28 | $1,455 | $52 |
| Acyclovir | 35 | $1,390 | $40 |
| Dexamethasone | 22 | $748 | $34 |
| Prednisone | 23 | $386 | $17 |
| Hydrocodone-Acetaminophen | 15 | $315 | $21 |
| Levofloxacin | 12 | $159 | $13 |
2022: 12 drugs
| Lenalidomide | 15 | $191,792 | $12,786 |
| Brukinsa | 15 | $177,030 | $11,802 |
| Promacta | 15 | $170,978 | $11,399 |
| Bosulif | 12 | $164,053 | $13,671 |
| Ninlaro | 13 | $151,665 | $11,667 |
| Jakafi | 12 | $103,528 | $8,627 |
| Venclexta | 12 | $31,082 | $2,590 |
| Dexamethasone | 25 | $1,417 | $57 |
| Hydroxyurea | 23 | $1,334 | $58 |
| Acyclovir | 26 | $1,143 | $44 |
| Prednisone | 16 | $258 | $16 |
| Hydrocodone-Acetaminophen | 12 | $221 | $18 |
2021: 10 drugs
| Revlimid | 56 | $975,266 | $17,415 |
| Bosulif | 21 | $281,961 | $13,427 |
| Promacta | 11 | $177,566 | $16,142 |
| Imbruvica | 19 | $172,744 | $9,092 |
| Venclexta | 20 | $57,222 | $2,861 |
| Acyclovir | 37 | $1,623 | $44 |
| Hydroxyurea | 24 | $1,351 | $56 |
| Hydrocodone-Acetaminophen | 17 | $286 | $17 |
| Gabapentin | 11 | $185 | $17 |
| Lorazepam | 11 | $82 | $7 |
2020: 13 drugs
| Revlimid | 61 | $1,008,719 | $16,536 |
| Imbruvica | 41 | $455,384 | $11,107 |
| Bosulif | 20 | $202,906 | $10,145 |
| Promacta | 12 | $186,347 | $15,529 |
| Venclexta | 16 | $72,509 | $4,532 |
| Imatinib Mesylate | 11 | $1,768 | $161 |
| Dexamethasone | 22 | $1,422 | $65 |
| Hydroxyurea | 26 | $1,369 | $53 |
| Acyclovir | 31 | $1,353 | $44 |
| Prednisone | 17 | $292 | $17 |
| Hydrocodone-Acetaminophen | 15 | $277 | $18 |
| Allopurinol | 13 | $98 | $8 |
| Lorazepam | 11 | $81 | $7 |
2019: 13 drugs
| Revlimid | 43 | $697,914 | $16,231 |
| Imbruvica | 55 | $608,526 | $11,064 |
| Promacta | 12 | $154,968 | $12,914 |
| Bosulif | 21 | $136,095 | $6,481 |
| Venclexta | 12 | $120,681 | $10,057 |
| Imatinib Mesylate | 12 | $8,622 | $718 |
| Dexamethasone | 24 | $1,463 | $61 |
| Hydroxyurea | 29 | $1,441 | $50 |
| Acyclovir | 18 | $464 | $26 |
| Anastrozole | 13 | $356 | $27 |
| Hydrocodone-Acetaminophen | 22 | $321 | $15 |
| Prednisone | 17 | $200 | $12 |
| Lorazepam | 14 | $97 | $7 |
2018: 15 drugs
| Revlimid | 35 | $532,544 | $15,216 |
| Pomalyst | 24 | $416,574 | $17,357 |
| Imbruvica | 20 | $252,832 | $12,642 |
| Jakafi | 15 | $181,567 | $12,104 |
| Promacta | 13 | $132,758 | $10,212 |
| Zytiga | 12 | $124,019 | $10,335 |
| Tasigna | 16 | $90,465 | $5,654 |
| Hydroxyurea | 42 | $2,638 | $63 |
| Dexamethasone | 26 | $1,421 | $55 |
| Acyclovir | 31 | $684 | $22 |
| Prednisone | 23 | $454 | $20 |
| Anastrozole | 12 | $317 | $26 |
| Hydrocodone-Acetaminophen | 13 | $243 | $19 |
| Ondansetron | 11 | $121 | $11 |
| Lorazepam | 15 | $109 | $7 |
2017: 19 drugs
| Jakafi | 22 | $401,016 | $18,228 |
| Imbruvica | 25 | $280,347 | $11,214 |
| Pomalyst | 12 | $185,762 | $15,480 |
| Bosulif | 14 | $138,929 | $9,923 |
| Revlimid | 12 | $134,698 | $11,225 |
| Zytiga | 12 | $111,924 | $9,327 |
| Tarceva | 12 | $102,560 | $8,547 |
| Promacta | 11 | $85,569 | $7,779 |
| Tasigna | 20 | $66,559 | $3,328 |
| Imatinib Mesylate | 18 | $22,069 | $1,226 |
| Hydroxyurea | 30 | $2,236 | $75 |
| Acyclovir | 41 | $1,037 | $25 |
| Dexamethasone | 19 | $507 | $27 |
| Hydrocodone-Acetaminophen | 12 | $472 | $39 |
| Ondansetron | 23 | $296 | $13 |
| Anastrozole | 11 | $281 | $26 |
| Prednisone | 12 | $256 | $21 |
| Atenolol | 13 | $122 | $9 |
| Lorazepam | 11 | $83 | $8 |
2016: 15 drugs
| Jakafi | 22 | $469,217 | $21,328 |
| Revlimid | 27 | $307,842 | $11,402 |
| Pomalyst | 16 | $217,532 | $13,596 |
| Imbruvica | 13 | $146,822 | $11,294 |
| Gleevec | 21 | $143,200 | $6,819 |
| Tarceva | 12 | $93,239 | $7,770 |
| Tasigna | 14 | $72,851 | $5,204 |
| Hydroxyurea | 27 | $2,862 | $106 |
| Acyclovir | 44 | $1,244 | $28 |
| Tamoxifen Citrate | 13 | $738 | $57 |
| Hydrocodone-Acetaminophen | 13 | $702 | $54 |
| Dexamethasone | 15 | $412 | $27 |
| Prednisone | 15 | $333 | $22 |
| Venlafaxine | 11 | $137 | $12 |
| Lorazepam | 12 | $101 | $8 |
2015: 14 drugs
| Revlimid | 57 | $611,102 | $10,721 |
| Sprycel | 13 | $137,726 | $10,594 |
| Gleevec | 12 | $116,877 | $9,740 |
| Tasigna | 15 | $105,562 | $7,037 |
| Tarceva | 13 | $93,011 | $7,155 |
| Zytiga | 11 | $88,466 | $8,042 |
| Hydroxyurea | 26 | $2,967 | $114 |
| Gabapentin | 11 | $1,446 | $131 |
| Tamoxifen Citrate | 21 | $1,247 | $59 |
| Hydrocodone-Acetaminophen | 21 | $1,021 | $49 |
| Acyclovir | 29 | $859 | $30 |
| Dexamethasone | 21 | $593 | $28 |
| Prednisone | 21 | $500 | $24 |
| Venlafaxine | 11 | $193 | $18 |
2014: 17 drugs
| Revlimid | 44 | $432,127 | $9,821 |
| Sprycel | 12 | $105,443 | $8,787 |
| Gleevec | 12 | $100,942 | $8,412 |
| Zytiga | 12 | $74,078 | $6,173 |
| Tarceva | 12 | $73,319 | $6,110 |
| Tasigna | 14 | $59,735 | $4,267 |
| Hydroxyurea | 28 | $2,231 | $80 |
| Tamoxifen Citrate | 22 | $1,400 | $64 |
| Anastrozole | 30 | $899 | $30 |
| Hydrocodone-Acetaminophen | 36 | $663 | $18 |
| Dexamethasone | 19 | $529 | $28 |
| Acyclovir | 18 | $466 | $26 |
| Venlafaxine | 11 | $461 | $42 |
| Prednisone | 18 | $289 | $16 |
| Allopurinol | 11 | $167 | $15 |
| Lorazepam | 17 | $149 | $9 |
| Hydrochlorothiazide | 12 | $103 | $9 |
2013: 10 drugs
| Revlimid | 38 | $337,909 | $8,892 |
| Gleevec | 12 | $116,087 | $9,674 |
| Hydroxyurea | 33 | $3,996 | $121 |
| Anastrozole | 74 | $2,521 | $34 |
| Tamoxifen Citrate | 22 | $1,341 | $61 |
| Gabapentin | 11 | $986 | $90 |
| Hydrocodone-Acetaminophen | 40 | $964 | $24 |
| Dexamethasone | 22 | $423 | $19 |
| Oxycodone | 12 | $347 | $29 |
| Allopurinol | 12 | $163 | $14 |
Professional record
- NPI
- 1750389250
- Licence
- CA A61497California A61497: Current · expires 2028-08-31
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2005-07-08
- NPI last updated
- 2025-07-21
- NPI record certified
- 2025-07-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 710 Lawrence Expy, Santa Clara, CA, 95051
This office lists an electronic records connection.